Trial Profile
A Long Term Documentation to Demonstrate Long Term Efficacy and Safety of Humira in Patients With Psoriatic Arthritis Under Conditions of Daily Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 13 Jul 2018 Results of minimal disease activity assessments (1684) published in the Rheumatology.
- 12 Jun 2016 Results assessing association between anti-citrullinated protein antibodies bone destruction (n=1996) published in the Rheumatology
- 15 Dec 2015 Results of retrospective analysis published in The Journal of Rheumatology